Skip to content
Screener

Solid Biosciences Inc. SLDB Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$120.85M-15.5%
Biogen logo
BiogenBIIB
$245.7M-26.5%
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
4.9%0.0pp
Insmed logo
InsmedINSM
$13.18M+27.8%
Regenxbio logo
RegenxbioRGNX
$43.87M-13.1%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$19.65M-17.7%

Other financials

Income statement

See full
Revenue$2.0M-40.6%
Operating income-$57.4M-37.6%
Net income-$54.8M-38.8%
EPS (diluted)-$0.38+9.5%

Balance sheet

See full
Cash & equivalents$159.4M+14.7%
Total debt$20.2M-12.6%
Total equity$374.1M+44.8%
Total assets$420.6M+36.4%

Cash flow

See full
Operating cash flow-$52.6M-40.6%
CapEx$150.0K-60.2%
Free cash flow-$52.7M-39.6%

Valuation

See full
Market cap$917.85M+94.8%
Enterprise value$778.61M+119%

Profitability

See full
Operating margin-1,315.2%-4,060pp
Net margin-1,062.3%-251,151pp
FCF margin-1,247.7%-9,569pp

Returns & leverage

See full
Return on equity-65.5%-2.5pp
Debt / equity0.1×0.0×
Current ratio13.8×+4.5×

Where this comes from

Reported directly by Solid Biosciences Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The source filing: Solid Biosciences Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:04 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-337935
Line itemJune 30, 2026December 31, 2025
Restricted cash, current6381,222
Total current assets395,108205,456
Non-current assets:
Operating lease, right-of-use assets20,66721,924
Property and equipment, net3,9594,169
Other non-current assets138223
Restricted cash, net of current portion708768
Total non-current assets25,47227,084

Item 1. Financial Statements (unaudited)

FAQ

What is Solid Biosciences Inc.'s operating lease ROU assets?
Solid Biosciences Inc. (SLDB) reported operating lease ROU assets of $20.67M in Q2 2026.
How has Solid Biosciences Inc.'s operating lease ROU assets changed year-over-year?
Solid Biosciences Inc.'s operating lease ROU assets decreased by 10.7% year-over-year, from $23.13M to $20.67M.
What is the long-term trend for Solid Biosciences Inc.'s operating lease ROU assets?
Over 5 years (2020 to 2025), Solid Biosciences Inc.'s operating lease ROU assets has grown at a 43.7% compound annual growth rate (CAGR), from $3.58M to $21.92M.
What does operating lease ROU assets mean?
Right-of-use assets representing the lessee's right to use leased property over the lease term under ASC 842 operating lease classification.

Ask your AI about Solid Biosciences Inc.'s operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude